Glaukos to Release Third Quarter 2024 Financial Results after Market Close on November 4
Glaukos (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, has announced plans to release its third quarter 2024 financial results after the market close on Monday, November 4, 2024. The company will host a conference call and simultaneous webcast to discuss the results at 1:30 p.m. PT (4:30 p.m. ET) on the same day.
Interested parties can access the live webcast through the company's investor relations website. To participate in the conference call, attendees should dial 888-210-2212 (U.S.) or 646-960-0390 (International) and enter Conference ID 7935742. A replay of the call will be made available on the company's website following the event's conclusion.
Glaukos (NYSE: GKOS), un'azienda farmaceutica e di tecnologia medica oftalmica, ha annunciato piani per rilasciare i suoi risultati finanziari del terzo trimestre 2024 dopo la chiusura del mercato lunedì 4 novembre 2024. L'azienda ospiterà una conferenza telefonica e un webcast simultaneo per discutere i risultati alle 13:30 PT (16:30 ET) lo stesso giorno.
Le parti interessate possono accedere al webcast live attraverso il sito web delle relazioni con gli investitori dell'azienda. Per partecipare alla conferenza telefonica, i partecipanti devono comporre il numero 888-210-2212 (USA) o 646-960-0390 (Internazionale) e inserire l'ID Conferenza 7935742. Una registrazione della chiamata sarà disponibile sul sito web dell'azienda dopo la conclusione dell'evento.
Glaukos (NYSE: GKOS), una empresa farmacéutica y de tecnología médica oftálmica, ha anunciado planes para publicar sus resultados financieros del tercer trimestre de 2024 después del cierre del mercado el lunes, 4 de noviembre de 2024. La empresa llevará a cabo una conferencia telefónica y una transmisión en vivo simultánea para discutir los resultados a la 1:30 p.m. PT (4:30 p.m. ET) el mismo día.
Las partes interesadas pueden acceder a la transmisión en vivo a través del sitio web de relaciones con los inversionistas de la empresa. Para participar en la conferencia telefónica, los asistentes deben marcar 888-210-2212 (EE. UU.) o 646-960-0390 (Internacional) e ingresar el ID de Conferencia 7935742. Una grabación de la llamada estará disponible en el sitio web de la empresa después de la conclusión del evento.
글라우코스(뉴욕증권거래소: GKOS)는 안과 제약 및 의료 기술 회사로, 2024년 11월 4일 월요일 시장 마감 후 2024년 3분기 재무 결과를 발표할 계획이라고 발표했습니다. 같은 날 오후 1시 30분 PT (오후 4시 30분 ET)에 결과를 논의하기 위한 컨퍼런스 콜과 동시 웹캐스트를 개최할 예정입니다.
관심 있는 분들은 회사의 투자자 관계 웹사이트를 통해 라이브 웹캐스트에 접근할 수 있습니다. 컨퍼런스 콜에 참여하려면 참석자가 888-210-2212 (미국) 또는 646-960-0390 (국제)로 전화하고 회의 ID 7935742를 입력해야 합니다. 행사 종료 후 회사 웹사이트에서 통화 녹화가 제공될 것입니다.
Glaukos (NYSE: GKOS), une entreprise pharmaceutique et de technologie médicale ophtalmique, a annoncé des projets pour publier ses résultats financiers du troisième trimestre 2024 après la fermeture du marché le lundi 4 novembre 2024. L'entreprise organisera une conférence téléphonique et un webcast simultané pour discuter des résultats à 13h30 PT (16h30 ET) le même jour.
Les parties intéressées peuvent accéder au webcast en direct via le site web des relations avec les investisseurs de l'entreprise. Pour participer à la conférence téléphonique, les participants doivent composer le 888-210-2212 (États-Unis) ou le 646-960-0390 (International) et entrer l'identifiant de conférence 7935742. Un replay de l'appel sera disponible sur le site de l'entreprise après la conclusion de l'événement.
Glaukos (NYSE: GKOS), ein ophthalmologisches Pharma- und Medizintechnologieunternehmen, hat Pläne angekündigt, seine finanziellen Ergebnisse des dritten Quartals 2024 nach Börsenschluss am Montag, den 4. November 2024, zu veröffentlichen. Das Unternehmen wird am selben Tag um 13:30 Uhr PT (16:30 Uhr ET) eine Telefonkonferenz sowie einen simultanen Webcast abhalten, um die Ergebnisse zu diskutieren.
Interessierte Parteien können über die Investor-Relations-Website des Unternehmens auf den Live-Webcast zugreifen. Um an der Telefonkonferenz teilzunehmen, sollten die Teilnehmer die Nummer 888-210-2212 (USA) oder 646-960-0390 (International) wählen und die Konferenz-ID 7935742 eingeben. Eine Aufzeichnung des Anrufs wird nach Abschluss der Veranstaltung auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
Conference Call and Webcast Scheduled for 1:30 p.m. PT
A link to the live webcast will be available on the company’s website at http://investors.glaukos.com. To participate in the conference call, please dial 888-210-2212 (
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241009112791/en/
Chris Lewis
Vice President, Investor Relations and Corporate Affairs
(949) 481-0510
clewis@glaukos.com
Source: Glaukos Corporation
FAQ
When will Glaukos (GKOS) release its Q3 2024 financial results?
What time is the Glaukos (GKOS) Q3 2024 earnings call scheduled for?
How can investors access the Glaukos (GKOS) Q3 2024 earnings call?
Will there be a replay available for the Glaukos (GKOS) Q3 2024 earnings call?
